Skin Conditions & Dermatology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

This Phase 3 study tested rocatinlimab, a new antibody treatment, in adolescents with moderate-to-severe atopic dermatitis, a condition causing itchy and inflamed skin. The trial included 187 participants from several countries and has completed with results now available. For patients and caregivers, rocatinlimab could represent a promising alternative that might improve skin symptoms while potentially reducing side effects compared to current treatments.

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

This ongoing Phase 3 trial is investigating lebrikizumab in children from 6 months up to 18 years old who have moderate-to-severe atopic dermatitis. With 377 participants enrolled across multiple countries, this study seeks to find new ways to ease symptoms and enhance quality of life for young patients living with eczema. If successful, lebrikizumab could become an important option for managing this common and challenging skin condition in children.

Dupilumab in the Treatment of Pediatric Alopecia Areata

This Phase 2 trial is testing dupilumab, an antibody therapy, in children and adolescents with moderate-to-severe alopecia areata, a condition that causes patchy hair loss. The study is currently recruiting in the United States and will follow participants for up to 124 weeks. For families affected by alopecia areata, dupilumab may offer a new treatment approach aimed at encouraging hair regrowth by targeting the immune system.

Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age

This Phase 3 trial is evaluating abrocitinib, an oral medication, for young children aged 2 to under 6 years with moderate-to-severe atopic dermatitis. The study plans to enroll 90 children and uses a double-blind design with treatment lasting up to 24 weeks. If proven safe and effective, abrocitinib could provide a simpler and more child-friendly treatment option for managing eczema symptoms in this young age group.

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

This Phase 2 trial is testing an injected form of the Gardasil-9 vaccine for people with warts that have not responded to standard treatments. Recruiting in the United States with 55 participants, the study explores whether this vaccine can directly target stubborn warts and help clear them more effectively. This approach could open up new possibilities for treating warts that are difficult to manage with existing therapies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.